We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 21, 2021

Mobocertinib in Platinum-Pretreated Patients With EGFRex20ins-Positive Metastatic NSCLC

JAMA Oncology


Additional Info

JAMA Oncology
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
JAMA Oncol 2021 Oct 14;[EPub Ahead of Print], C Zhou, SS Ramalingam, TM Kim, SW Kim, JC Yang, GJ Riely, T Mekhail, D Nguyen, MR Garcia Campelo, E Felip, S Vincent, S Jin, C Griffin, V Bunn, J Lin, HM Lin, M Mehta, PA Jänne

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading